Alloy Therapeutics
Agent39Agent Readiness: 39/100. Below median. Measured by StartupHub.ai. Median 41.Trust82Data Trust: 82/100. Top 25%. Measured by StartupHub.ai. Median 61.A biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services.
About this profileCompany details: from public sourcesFunding: no announced round on fileOwnership: not yet claimed by the companyScores: measured by named tools; each links to its methodOur rules
About
Alloy Therapeutics is a biotechnology ecosystem company focused on accelerating drug discovery and development. They leverage AI-driven platforms and integrated services to support the entire process, evolving from an antibody discovery pioneer to a full-stack biotech infrastructure provider. Their offerings aim to streamline and enhance the efficiency of bringing new therapeutics to market.
Listed competitors
A global contract research organization specializing in preclinical and translational oncology research.
Life science company pioneering drug discovery with AI and advanced technologies.
Drug discovery services company specializing in small molecule drug discovery and medicinal chemistry.
Biotechnology services company specializing in antibody discovery and development.
CDMO providing process development, analytical services, and cGMP API manufacturing for drug candidates.
Biotechnology firm specializing in antibody development, production, and biological research tools.
Developer and manufacturer of antibodies and reagents for biomedical research.
Also in this space
AI-guided drug discovery platform for tissue-targeted medicines.
Shares Biotech, Drug Discovery
Leveraging AI and a massive patient tissue dataset to accelerate drug discovery and advance precision medicine.
Shares Biotechnology, Artificial Intelligence
Automated wet lab for AI-driven protein design, enabling rapid synthesis, expression, and testing of thousands of protein designs.
Shares Biotechnology, Artificial Intelligence
Developing gene editing therapies to lower cholesterol.
Shares Biotechnology, Drug Delivery
Earendil Labs is an AI biotechnology company focused on leveraging artificial intelligence for drug discovery and development of next-generation biologics.
Shares Biotechnology, Artificial Intelligence
Key facts
- Website
- alloytx.com
- Headquarters
- Boston, Massachusetts, USA
- Founded
- 2017
- Total funding
- $157M (Series E)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Post-money | Lead investors |
|---|---|---|---|---|
| 15 Apr 2026 | Series E | $40M | $1.0B | |
| 3 Oct 2022 | Series D | $42M | Mubadala Capital, 8VC | |
| 2 Apr 2021 | Series C | $75M | Presight Capital, Peter Thiel, 8VC |
Tech stack
Detected on alloytx.com, last scanned 22 Oct 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Tag Manager
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Google Workspace
- Cookie consent
- Cookiebot
- Visitor tracking
- ZoomInfo WebSights
Alloy Therapeutics scores 46. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Alloy Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Alloy Therapeutics is 82 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Alloy Therapeutics raised?
Alloy Therapeutics has raised a total of $157M in funding. The most recent round on record is Series E.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Alloy Therapeutics
